Clinical Trial: A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07023627) titled 'A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression' on June 09.

Brief Summary: This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.

Study Start Date: Aug. 30

Study Type: INTERVENTIONAL

Condition: Ovarian Cancer

Intervention: DRUG: INCB123667

Administered orally twice daily (BID).

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Incyte Corporation

Published by HT Digital Content Services with permission from Health Daily Digest....